Tetralogic Pharmaceuticals (OTCMKTS: TLOG) and Grifols SA, Barcelona (NASDAQ:GRFS) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, institutional ownership, analyst recommendations, risk and profitability.
This is a summary of current ratings and target prices for Tetralogic Pharmaceuticals and Grifols SA, Barcelona, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Grifols SA, Barcelona||0||1||3||0||2.75|
Valuation and Earnings
This table compares Tetralogic Pharmaceuticals and Grifols SA, Barcelona’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Tetralogic Pharmaceuticals||N/A||N/A||-$49.72 million||($1.65)||-0.03|
|Grifols SA, Barcelona||$4.48 billion||3.33||$603.60 million||$0.93||23.52|
Grifols SA, Barcelona has higher revenue and earnings than Tetralogic Pharmaceuticals. Tetralogic Pharmaceuticals is trading at a lower price-to-earnings ratio than Grifols SA, Barcelona, indicating that it is currently the more affordable of the two stocks.
This table compares Tetralogic Pharmaceuticals and Grifols SA, Barcelona’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Grifols SA, Barcelona||13.16%||18.08%||6.22%|
Volatility & Risk
Tetralogic Pharmaceuticals has a beta of 2.82, indicating that its stock price is 182% more volatile than the S&P 500. Comparatively, Grifols SA, Barcelona has a beta of 1.04, indicating that its stock price is 4% more volatile than the S&P 500.
Insider & Institutional Ownership
0.0% of Tetralogic Pharmaceuticals shares are owned by institutional investors. Comparatively, 22.5% of Grifols SA, Barcelona shares are owned by institutional investors. 15.4% of Tetralogic Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Grifols SA, Barcelona pays an annual dividend of $0.28 per share and has a dividend yield of 1.3%. Tetralogic Pharmaceuticals does not pay a dividend. Grifols SA, Barcelona pays out 30.1% of its earnings in the form of a dividend.
Grifols SA, Barcelona beats Tetralogic Pharmaceuticals on 9 of the 12 factors compared between the two stocks.
Tetralogic Pharmaceuticals Company Profile
TetraLogic Pharmaceuticals Corporation is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics in oncology, infectious diseases and autoimmune diseases. The Company’s segment is the identification and development of novel small molecule therapies in oncology and infectious diseases. The Company has approximately two clinical-stage product candidates in development, such as birinapant and SHAPE. SHAPE is the Company’s histone deacetylase (HDAC) inhibitor that it is developing for topical use for the treatment of early-stage cutaneous T-cell lymphoma (CTCL). The Company is also exploring studying SHAPE in alopecia areata, an autoimmune skin disease. SHAPE has been granted the United States orphan drug designation for CTCL. Birinapant is a small molecule therapeutic that mimics Second Mitochondrial Activator of Caspases (SMAC)-mimetic, which leads to apoptosis or cell-death in damaged cells.
Grifols SA, Barcelona Company Profile
Grifols, S.A., a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company specializes in providing infusion solutions, nutrition products, and medical devices for use in hospitals and clinics. It operates through four segments: Bioscience, Diagnostic, Hospital, and Raw Materials and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use, including the reception, analysis, quarantine, classification, fractionation, and purification of plasma; and sells and distributes end products. This segment offers plasma products, such as IVIG, Factor VIII, A1PI, and albumin; and intramuscular immunoglobulins, ATIII, Factor IX, and plasma thromboplastin components. The Diagnostic segment focuses on researching, developing, manufacturing, and marketing in vitro diagnostics products comprising analytical instruments, reagents, software, and related products for use in clinical and blood bank laboratories. This segment serves blood donation centers, clinical analysis laboratories, and hospital immunohematology services. The Hospital segment manufactures and installs products used by hospitals consisting of parenteral solutions, and enteral and parenteral nutritional fluids. The Raw Materials and Others segment sells intermediate biological products; and renders manufacturing services to third party companies. The company also offers engineering services. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves hospitals and clinics, group purchasing organizations, governments, and other distributors through sales representatives, marketing partners, and third-party distributors. Grifols, S.A. was founded in 1940 and is headquartered in Barcelona, Spain.
What are top analysts saying about Tetralogic Pharmaceuticals Corp? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Tetralogic Pharmaceuticals Corp and related companies.